Amgen files BLA for migraine med erenumab

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (AMGN +0.1%) files a Biologics License Application (BLA) with the FDA seeking approval of erenumab for the prevention of migraine. If approved, it will co-promote the CGRP receptor inhibitor with Novartis (NVS +0.3%).

Previously: Amgen to co-promote migraine med erenumab with Novartis in U.S. (April 24)

Previously: Amgen's erenumab successful in second late-stage migraine study; shares up 1% after hours (Nov. 16, 2016)